natgillin/translations-raw huggingface dataset:
In clinical study AI424-020, paediatric patients 3 months to less than 18 years of age who received either the oral powder or capsule formulation had a mean duration of treatment with atazanavir of 115 weeks. 
U kliničkom ispitivanju AI424-020 u pedijatrijskih bolesnika u dobi od 3 mjeseca do manje od 18 godina koji su primali ili oblik oralnog prašaka ili oblik kapsule, medijan trajanja liječenja iznosio je 115 tjedana.
The geometric mean (CV%) for atazanavir Cmin and AUC was 654 (76%) ng/ml and 44185 (51%) ng•h/ml, respectively. 
Geometrijska sredina (CV%) Cmin atazanavira iznosila je 654 (76%) ng/ml, a AUC atazanavira 44185 (51%) ng•h/ml.
In a small number of patients without a functional CYP2C19 allele, significantly increased voriconazole exposures are expected (see section 4.5). 
U malog broja bolesnika bez funkcionalnog CYP2C19 alela očekuje se značajno povećanje izloženosti vorikonazolu (vidjeti dio 4.5).
Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) Lamivudine 150 mg twice daily + zidovudine 300 mg twice daily 
Nukleozidni/nukleotidni inhibitori reverzne transkriptaze (NRTI-jevi) Lamivudin 150 mg dvaput na dan + zidovudin 300 mg dvaput na dan
Regular monitoring of the renal function of patients should be maintained throughout the treatment duration (see section 4.8). 
Redovito praćenje bubrežnih funkcija u bolesnika treba se održavati tijekom cijelog trajanja liječenja (pogledajte dio4.8).
Systemic corticosteroid effects including Cushing's syndrome and adrenal suppression have been reported in patients receiving ritonavir and inhaled or intranasally administered fluticasone propionate; this could also occur with other corticosteroids metabolised via the P450 3A pathway, e.g., budesonide. 
Sistemski učinci kortikosteroida, uključujući Cushingov sindrom i supresiju nadbubrežne žlijezde, zabilježeni su u bolesnika koji su primali ritonavir i inhalirali ili intranazalno primjenjivali flutikazon propionat; to se može dogoditi i s drugim kortikosteroidima koji se metaboliziraju putem P450
The co-administration of abacavir and atazanavir is not expected to significantly alter the exposure of abacavir. 
Ne očekuje se da će istovremena primjena abakavira i atazanavira značajno promijeniti izloženost abakaviru.
They work by reducing the amount of HIV in your body and this in turn, strengthens your immune system. 
Djeluju tako što smanjuju količinu HIVa u Vašem tijelu, što jača
The decrease in AUC, Cmax, and Cmin was not mitigated when an increased dose of atazanavir /ritonavir (400/100 mg once daily) was temporally separated from omeprazole by 12 hours. 
Smanjenje AUC, Cmax i Cmin nije bilo ublaženo privremenim vremenskim razmakom između povišene doze atazanavira s ritonavirom (400/100 mg jedanput na dan) i omeprazola od 12 sati.
Atazanavir given without ritonavir should not be considered in patients treated with a backbone regimen containing tenofovir disoproxil and with other concomitant medications that reduce atazanavir bioavailability (see section 4.5 In case of withdrawal of ritonavir from the recommended atazanavir boosted regimen) or in case of perceived challenging compliance. 
Primjena atazanavira bez ritonavira ne smije se razmatrati u bolesnika liječenih osnovnim režimom koji sadrži tenofovirdizoproksil i drugim istovremeno primjenjivanim lijekovima koji smanjuju bioraspoloživost atazanavira (vidjeti odlomak 'Ako se ritonavir izostavi iz preporučenog režima liječenja atazanavirom pojačanim ritonavirom' u dijelu 4.5), kao ni u bolesnika za koje se smatra da bi mogli imati poteškoća s pridržavanjem liječenja.
Ten patients had baseline phenotypic resistance to atazanavir + ritonavir (fold change [FC]>5.2). 
Deset bolesnika imalo je na početku fenotipsku rezistenciju na atazanavir s ritonavirom (promjena ekspresije [FC] >5,2 puta).
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported; 
Prijavljena je pojava autoimunih bolesti (kao Gravesova bolest i autoimunog hepatitisa ) kao dio imunološke reaktivacije.
- The other ingredients are lactose monohydrate (see section 2, ‘Atazanavir Mylan contains lactose'), crospovidone, magnesium stearate. 
- Drugi su sastojci laktoza hidrat, (vidjeti dio 2 „Atazanavir Mylan sadrži laktozu”), krospovidon, magnezijev stearat.
Coadministration of a single 300 mg dose of atazanavir and 100 mg dose of ritonavir with a light meal resulted in a 33% increase in the AUC and a 40% increase in both the Cmax and the 24 hour concentration of atazanavir relative to the fasting state. 
Istovremena primjena jednokratne doze atazanavira od 300 mg i doze ritonavira od 100 mg uz lagani obrok rezultirala je povećanjem AUC-a za 33% i povećanjem Cmax i 24-satne koncentracije atazanavira za 40% u odnosu na primjenu natašte.
In patients with pre-existing conduction problems (second degree or higher atrioventricular or complex bundle-branch block), Atazanavir Mylan should be used with caution and only if the benefits exceed the risk (see section 5.1). 
U bolesnika s već prisutnim poremećajima provođenja (atrioventrikularni blok drugog ili višeg stupnja ili kompletni blok grane) Atazanavir Mylan treba primjenjivati s oprezom i samo ako su koristi od liječenja veće od rizika (vidjeti dio 5.1).
- in patients with at least one functional CYP2C19 allele, close clinical monitoring for a loss of both voriconazole (clinical signs) and atazanavir (virologic response) efficacy is recommended. 
- za bolesnike s najmanje jednim funkcionalnim CYP2C19 alelom preporučuje se poman klinički nadzor kako bi se uočio eventualni gubitak djelotvornosti vorikonazola (klinički znakovi) i atazanavira (virološki odgovor).
Mean urinary excretion of unchanged drug was 7% following 2 weeks of dosing at 800 mg once daily. 
Prosječno se 7% lijeka izlučilo mokraćom u neizmijenjenom obliku nakon 2 tjedna primjene doze od 800 mg jedanput na dan.
• simvastatin and lovastatin (used to lower blood cholesterol). 
• simvastatin i lovastatin (primjenjuju se za snižavanje kolesterola u krvi)
• It is not recommended to use atazanavir with ritonavir for pregnant patients who are receiving both tenofovir disoproxil and an H2-receptor antagonist. 
• Ne preporučuje se primjenjivati atazanavir s ritonavirom u trudnica koje primaju i tenofovirdizoproksil i antagonist
In previous studies, the pharmacokinetics of atazanavir was not altered by rifabutin. 
U prethodnim ispitivanjima, rifabutin nije promijenio farmakokinetiku atazanavira.
HIV RNA <100,000 copies/ml 
HIV RNK <100 000 kopija/ml
Co-administration with atazanavir has the potential to increase or decrease warfarin concentrations. 
Istovremena primjena s atazanavirom može povisiti ili sniziti koncentracije varfarina.
This effect may be due to an induction of CYP3A4. 
Taj učinak možda nastaje zbog indukcije enzima CYP3A4.
Concentrations of these antiarrhythmics may be increased when co-administered with atazanavir. 
Koncentracije ovih antiaritmika mogu biti povišene kad se primjenjuju istovremeno s atazanavirom.
Co-administration with simvastatin or lovastatin (see section 4.5). 
Istovremena primjena sa simvastatinom ili lovastatinom (vidjeti dio 4.5).
In a fertility and early embryonic development study in rats, atazanavir altered oestrus cycling with no effects on mating or fertility. 
U ispitivanju učinaka na plodnost i rani embrionalni razvoj, atazanavir je promijenio ciklus estrusa bez učinaka na parenje ili plodnost.
110 (n=83) 122 (n=60) 121 (n=94) 154 (n=60) NA 
CD4 prosječna promjena od početne vrijednosti, stanice/mm Svi bolesnici 110 (n=83) 122 (n=60) 121 (n=94) 154 (n=60) NP
Among 1,151 patients receiving atazanavir 400 mg once daily, 177 patients were co-infected with chronic hepatitis B or C, and among 655 patients receiving atazanavir 300 mg once daily with ritonavir 100 mg once daily, 97 patients were co-infected with chronic hepatitis B or C. Co-infected patients were more likely to have baseline hepatic transaminase elevations than those without chronic viral hepatitis. 
Od 1151 bolesnika koji su primali atazanavir 400 mg jedanput na dan, 177 bolesnika istovremeno je imalo kroničnu infekciju virusom hepatitisa B ili C, dok je od 655 bolesnika koji su primali atazanavir 300 mg jedanput na dan s ritonavirom 100 mg jedanput na dan, 97 bolesnika istovremeno imalo kroničnu infekciju virusom B ili C.
Through 96 weeks of treatment, mean HIV RNA changes from baseline for atazanavir + ritonavir and lopinavir + ritonavir met criteria for non-inferiority based on observed cases. 
Nakon 96 tjedana liječenja, prosječna promjena razine HIV RNK u odnosu na početnu vrijednost uz atazanavir s ritonavirom i lopinavir s ritonavirom zadovoljila je kriterij neinferiornosti na temelju opaženih slučajeva.
QT prolongation 
Produljenje QT intervala
1 hour before taking Atazanavir Mylan or 2 hours after taking Atazanavir Mylan, H2-blockers like famotidine and proton pump inhibitors like omeprazole) 
Atazanavir Mylan, H2-blokatore kao famotidin ili inhibitore protonske pumpe kao omeprazol)
Atazanavir and fluconazole concentrations were not significantly modified when Atazanavir /ritonavir was co-administered with fluconazole. 
Koncentracije atazanavira i flukonazola nisu bile značajno promijenjene kad se atazanavir s ritonavirom primjenjivao istovremeno s flukonazolom.
Amiodarone, Systemic lidocaine, Quinidine 
Sistemski lidokain, Kinidin
uncommon: weight decreased, weight gain, anorexia, appetite increased 
manje često: smanjenje tjelesne težine, povećanje tjelesne težine, anoreksija, pojačan apetit
The recommended dose of Atazanavir Mylan capsules for adults is 300 mg once daily with 100 mg ritonavir once daily, taken with food, in combination with other anti-HIV medicines. 
Preporučena doza Atazanavir Mylan kapsula za odrasle je 300 mg jedanput na dan sa 100 mg ritonavira jedanput na dan i s hranom, u kombinaciji s drugim anti-HIV lijekovima.
For treatment-experienced paediatric patients, the mean baseline CD4 cell count was 522 cells/mm 
U prethodno liječenih pedijatrijskih bolesnika, prosječni početni broj CD4 stanica iznosio je 522 stanica/mm
HIV RNA <50 copies/ml, % All patients d 
HIV RNK <50 kopija/ml, % Svi bolesnici d
Concomitant use of salmeterol and Atazanavir Mylan may result in increased cardiovascular adverse events associated with salmeterol. 
Istovremena primjena salmeterola i lijeka Atazanavir Mylan može rezultirati pojačanim kardiovaskularnim nuspojavama salmeterola.
Carbamazepine should be used with caution in combination with atazanavir. 
Karbamazepin se mora primjenjivati uz oprez u kombinaciji s atazanavirom.
Co-administration of lurasidone with atazanavir is contraindicated as this may increase lurasidone-related toxicity (see section 4.3). 
Istodobna primjena lurasidona s atazanavirom kontraindicirana je jer može povećati toksičnost povezanu s primjenom lurasidona (vidjeti dio 4.3.).
• disorientation, amnesia (loss of memory), dizziness, somnolence (sleepiness), abnormal dream 
• dezorijentacija, amnezija (gubitak pamćenja), omaglica, somnolencija (izrazita pospanost),
What you need to know before you take Atazanavir Mylan 
Što morate znati prije nego počnete uzimati Atazanavir Mylan
In HIV-infected patients (n=13), multiple dosing of atazanavir 400 mg (without ritonavir) once daily with food produced a geometric mean (CV%) for atazanavir Cmax of 2298 (71) ng/ml, with time to Cmax of approximately 2.0 hours. 
U bolesnika zaraženih HIV-om (n=13), višestruka primjena atazanavira u dozi od 400 mg (bez ritonavira) jedanput na dan s hranom dovela je do geometrijske srednje vrijednosti (CV%) Cmax atazanavira od 2298 (71) ng/ml, uz vrijeme do postizanja Cmax od približno 2,0 sati.
Atazanavir Mylan with ritonavir should be used with caution in patients with mild hepatic impairment. 
Atazanavir Mylan s ritonavirom treba primjenjivati s oprezom u bolesnika s blagim oštećenjem funkcije jetre.
• medicines containing St. John's wort (Hypericum perforatum, a herbal preparation). 
• lijekove koji sadrže gospinu travu (Hypericum perforatum, biljni pripravak)
The most frequently reported laboratory abnormalities in paediatric patients receiving atazanavir oral powder was elevation of total bilirubin (≥ 2.6 times ULN, Grade 3-4; 16%) and increased amylase (Grade 3-4; 33%), generally of non-pancreatic origin. 
Najčešće zabilježeni poremećaj laboratorijskih nalaza u pedijatrijskih bolesnika koji su primali atazanavir oralni prašak bilo je povišenje ukupnog bilirubina (≥ 2,6 GGN, 3.-4. stupanj; 16%) i povišena vrijednost amilaze (3.-4. stupanj; 33%), općenito porijekla koje nije povezano s gušteračom.
Co-administration of quetiapine with atazanavir is contraindicated as atazanavir may increase quetiapine-related toxicity. 
Istodobna primjena kvetiapina i atazanavira je kontraindicirana jer atazanavir može povećati toksičnost povezanu s primjenom kvetiapina.
If the combination is judged unavoidable, close clinical monitoring is recommended in combination with an increase in the dose of atazanavir to 400 mg with 100 mg of ritonavir; doses of proton pump inhibitors comparable to omeprazole 20 mg should not be exceeded (see section 4.4). 
Ako se prosudi da je ta kombinacija neizbježna, preporučuje se pažljiv klinički nadzor u kombinaciji s povišenjem doze atazanavira na 400 mg sa 100 mg ritonavira; ne smiju se prekoračiti doze inhibitora protonske pumpe usporedive s dozom omeprazola od 20 mg (vidjeti dio 4.4).
Total rifabutin and 25-O-desacetylrifabutin AUC ↑119% (↑78% 
AUC ukupnog rifabutina i 25-Odezacetil-rifabutina ↑119% (↑78%
Atazanavir Mylan dose once daily (mg) 
Doza lijeka Atazanavir Mylan jedanput na dan (mg)
No dosage adjustment is necessary if methadone is co-administered with atazanavir. 
Nije potrebna prilagodba doze ako se metadon primjenjuje istovremeno s atazanavirom.
Therefore, Atazanavir Mylan is contraindicated with medicinal products that are substrates of CYP3A4 and have a narrow therapeutic index: quetiapine, lurasidone, alfuzosin, astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil, triazolam, orally administered midazolam, and ergot alkaloids, particularly ergotamine and dihydroergotamine (see section 4.3). 
Stoga je Atazanavir Mylan kontraindicirano primijeniti s lijekovima koji su supstrati enzima CYP3A4 i imaju uzak terapijski raspon, kao što su: kvetiapin, lurasidon, alfuzozin, astemizol, terfenadin, cisaprid, pimozid, kinidin, bepridil, triazolam, peroralno primijenjen midazolam i alkaloidi ergota, osobito ergotamin i dihidroergotamin (vidjeti dio 4.3).
In female mice, atazanavir exposure at a dose that produced single-cell necrosis was 12 times the exposure in humans given 400 mg once daily. 
U ženki miša, izloženost atazanaviru u dozi koja je izazvala nekrozu pojedinačnih stanica bila je 12 puta veća od izloženosti u ljudi koji su dobivali 400 mg jedanput na dan.
Co-administration of atazanavir with other hormonal contraceptives or oral contraceptives containing progestogens other than norgestimate or norethindrone has not been studied, and therefore should be avoided (see section 4.5). 
Nije ispitana istovremena primjena atazanavira i druge hormonske ili oralne kontracepcije koja sadrži progestagene, osim norgestimata ili noretindrona, te se stoga mora izbjegavati (vidjeti dio 4.5).
* In a combined analysis from several clinical studies, atazanavir/ritonavir 300/100 mg coadministered with tenofovir disoproxil fumarate 300 mg (n=39) was compared to atazanavir/ritonavir 300/100 mg (n=33). 
* U kombiniranoj analizi nekoliko kliničkih ispitivanja, atazanavir/ritonavir 300/100 mg primijenjeni istovremeno s tenofovirdizoproksilfumaratom 300 mg (n=39) uspoređivani su s atazanavirom/ritonavirom 300/100 mg (n=33).
The geometric mean (CV%) for atazanavir Cmin and AUC were 120 (109) ng/ml and 14874 (91) ng•h/ml, respectively. 
Geometrijska srednja vrijednost (CV%) Cmin atazanavira iznosila je 120 (109) ng/ml, a AUC atazanavira 14874 (91) ng•h/ml.
Atazanavir, the active substance of Atazanavir Mylan, is excreted in human milk. 
Atazanavir, djelatna tvar lijeka Atazanavir Mylan izlučuje se u majčino mlijeko.
There were fewer treatment discontinuations in the unboosted atazanavir group (1 vs. 4 subjects in the atazanavir + ritonavir group). 
Zabilježen je manji broj prekida liječenja u skupini liječenoj nepojačanim atazanavirom (1 naspram 4 ispitanika u skupini koja je primala atazanavir + ritonavir).
Co-administration with products containing St. John's wort (Hypericum perforatum) (see section 4.5). 
Istovremena primjena s lijekovima koji sadrže gospinu travu (Hypericum perforatum) (vidjeti dio 4.5).
In an open-label, randomised, comparative study following a 26- to 30-week induction phase with atazanavir 300 mg + ritonavir 100 mg once daily and two NRTIs, unboosted atazanavir 400 mg once daily and two NRTIs administered during a 48-week maintenance phase (n=87) had similar antiviral efficacy compared with atazanavir + ritonavir and two NRTIs (n=85) in HIV infected subjects with fully suppressed HIV replication, as assessed by the proportion of subjects with HIV RNA < 50 copies/ml: 78% of subjects on unboosted atazanavir and two NRTIs compared with 75% on atazanavir + ritonavir and two NRTIs. 
U otvorenom, randomiziranom, usporednom ispitivanju provedenom nakon 26 do 30 tjednog uvodnog liječenja atazanavirom u dozi od 300 mg + ritonavirom u dozi od 100 mg jedanput na dan i dvama NRTI-ma u ispitanika s HIV infekcijom i potpuno suprimiranom replikacijom HIV-a, kombinacija nepojačanog atazanavira u dozi od 400 mg jedanput na dan i dvaju NRTI-ja tijekom 48-tjedne faze održavanja (n=87) postigla je sličnu antivirusnu djelotvornost kao i atazanavir + ritonavir i dva NRTI-ja (n=85), što je utvrđeno na temelju udjela ispitanika s HIV RNK < 50 kopija/ml: 78% ispitanika liječenih nepojačanim atazanavirom i dvama NRTI-ma u usporedbi sa 75% ispitanika liječenih atazanavirom s ritonavirom i dvama NRTI-ma.
Your doctor should do blood tests prior you starting to take this medicine and during treatment. 
Vaš liječnik treba napraviti krvne pretrage prije početka liječenja lijekom Atazanavir Mylan i tijekom liječenja.
• pancreatitis (inflammation of the pancreas), gastritis (inflammation of the stomach), stomatitis aphthous (mouth ulcers and cold sores), dysgeusia (impairment of the sense of taste), flatulence 
• pankreatitis (upala gušterače), gastritis (upala želuca), aftozni stomatitis (ranice u ustima i groznica na usnama), disgeuzija (promjene osjeta okusa), flatulencija (vjetrovi), suha usta,
At baseline, 34% of patients were receiving a PI and 60% were receiving an NNRTI. 
Na početku je 34% bolesnika primalo inhibitor proteaze, a 60% je primalo neki NNRTI.
Three of 20 infants (15%) born to women treated with atazanavir/ritonavir 300/100 mg and four of 20 infants (20%) born to women treated with atazanavir/ritonavir 400/100 mg experienced grade 3-4 bilirubin. 
Troje od 20 dojenčadi (15%) žena liječenih s atazanavirom/ritonavirom 300/100 mg i četvero od 20 dojenčadi (20%) žena liječenih s atazanavirom/ritonavirom 400/100 mg imalo je bilirubin 3.-4. stupnja.
The most frequently reported laboratory abnormality in paediatric patients receiving atazanavir was elevation of total bilirubin (≥ 2.6 times ULN, Grade 3-4) which occurred in 45% of patients. 
Najčešće zabilježeni poremećaj laboratorijskih nalaza u pedijatrijskih bolesnika koji su primali atazanavir bilo je povišenje ukupnog bilirubina (≥ 2,6 puta iznad gornje granice normale, 3.-4. stupanj), koje je nastalo u 45% bolesnika.
HIV RNA Mean Change from Baseline, log10 copies/ml All patients 
HIV RNK prosječna promjena od početne vrijednosti, log10 kopija/ml Svi bolesnici
• If tenofovir disoproxil or an H2-receptor antagonist is needed, a dose increase to atazanavir 400 mg with ritonavir 100 mg with TDM may be considered (see sections 4.6 and 5.2). 
• Ako je potrebno primijeniti tenofovirdizoproksil ili antagonist H2-receptora, možda će trebati razmotriti povećanje doze atazanavira na 400 mg primijenjeno s ritonavirom od 100 mg uz praćenje koncentracije lijeka (vidjeti dijelove 4.6 i 5.2).
Among patients who received atazanavir 400 mg once daily or atazanavir 300 mg with ritonavir 100 mg once daily, the only adverse reactions of any severity reported very commonly with at least a possible relationship to regimens containing atazanavir and one or more NRTIs were nausea (20%), diarrhoea (10%), and jaundice (13%). 
Među bolesnicima koji su primali atazanavir 400 mg jedanput na dan ili atazanavir 300 mg s ritonavirom 100 mg jedanput na dan, jedine vrlo često zabilježene nuspojave bilo koje težine s barem mogućom povezanošću s protokolima koji sadrže atazanavir i jedan ili više NRTI-jeva bile su mučnina (20%), proljev (10%) i žutica (13%).
Co-administration of atazanavir with grazoprevir-containing products, including elbasvir/grazoprevir fixed dose combination (used to treat chronic hepatitis C infection) is contraindicated because of the increase in grazoprevir and elbasvir plasma concentrations and potential for the increase in risk of ALT elevations associated with increased grazoprevir concentrations (see section 4.3). 
Istodobna primjena atazanavira s lijekovima koji sadrže grazoprevir, uključujući fiksnu dozu kombinacije elbasvira/grazoprevira (koja se koristi u liječenju kronične infekcije virusom hepatitisa C) kontraindicirana je zbog povišene koncentracije grazoprevira i elbasvira u plazmi te postoji rizik povišenja vrijednosti ALT-a zbog povećane koncentracije grazoprevira (vidjeti dio 4.3).
Frequency de novo PI substitution (n=26) 
Učestalost de novo supstitucija za rezistenciju na inhibitor proteaze (n=26)
Ethinyloestradiol Cmax ↑15% (↓1% 
Etinilestradiol Cmax ↑15% (↓1%
No significant effect on atazanavir concentrations was observed. 
Nisu opaženi značajni učinci na koncentracije atazanavira.
25-O-desacetyl-rifabutin AUC 
25-O-dezacetil -rifabutin Cmin
Adverse reactions were consistent between patients who received atazanavir 400 mg once daily and patients who received atazanavir 300 mg with ritonavir 100 mg once daily, except that jaundice and elevated total bilirubin levels were reported more frequently with atazanavir plus ritonavir. 
Nuspojave u bolesnika koji su primali atazanavir 400 mg jedanput na dan bile su sukladne nuspojavama u bolesnika koji su primali atazanavir 300 mg s ritonavirom 100 mg jedanput na dan, osim što su žutica i povišene razine ukupnog bilirubina bile zabilježene češće uz atazanavir s ritonavirom.
Voriconazole Cmax ↑438% (↑355% 
Vorikonazol Cmax ↑438% (↑355%
Asymptomatic first- and second-degree AV block was reported in paediatric patients (see section 4.8). 
U pedijatrijskih je bolesnika bio zabilježen asimptomatski AV blok prvog i drugog stupnja (vidjeti dio 4.8).
Co-administration with atazanavir may result in increased concentrations of the PDE5 inhibitor and an increase in PDE5-inhibitor-associated adverse events. 
Istovremena primjena s atazanavirom može rezultirati povišenim koncentracijama inhibitora PDE5 i pojačanim nuspojavama povezanima s inhibitorom PDE5.
HDPE bottle with polypropylene screw cap containing 30, 90 capsules. 
Boca od polietilena visoke gustoće (HDPE) s navojnim čepom od polipropilena koja sadrži 30, 90 kapsula.
Norgestimate AUC ↑85% (↑67% 
Norgestimat AUC ↑85% (↑67%
Quinidine has a narrow therapeutic window and is contraindicated due to potential inhibition of CYP3A by atazanavir. 
Kinidin ima uzak terapijski raspon i kontraindiciran je zbog moguće inhibicije enzima CYP3A atazanavirom.
HERBAL PRODUCTS St. John's wort (Hypericum perforatum) 
Gospina trava (Hypericum perforatum)
Talk to your doctor immediately if you get dark (tea-colored) urine, itching, yellowing of your skin or the white part of your eyes, pain around the stomach, pale colored stools or nausea. 
Odmah se obratite liječniku ako Vaša mokraća postane tamnija (boje poput čaja), ako se razviju svrbež, žutilo kože ili bjeloočnica, bol u trbuhu, blijeda stolica ili mučnina.
Sildenafil, tadalafil, and vardenafil are metabolised by CYP3A4. 
Sildenafil, tadalafil, vardenafil Sildenafil, tadalafil i vardenafil metabolizira enzim CYP3A4.
Norethindrone Cmin ↑262% (↑157% 
Noretindron Cmin ↑262% (↑157%
uncommon: hypersensitivity 
manje često: preosjetljivost
LIPID LOWERING AGENTS HMG- CoA reductase inhibitors Simvastatin 
Inhibitori reduktaze HMG-CoA Simvastatin